These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

920 related articles for article (PubMed ID: 16123173)

  • 1. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation.
    Poole KE; van Bezooijen RL; Loveridge N; Hamersma H; Papapoulos SE; Löwik CW; Reeve J
    FASEB J; 2005 Nov; 19(13):1842-4. PubMed ID: 16123173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteocyte recruitment declines as the osteon fills in: interacting effects of osteocytic sclerostin and previous hip fracture on the size of cortical canals in the femoral neck.
    Power J; Doube M; van Bezooijen RL; Loveridge N; Reeve J
    Bone; 2012 May; 50(5):1107-14. PubMed ID: 22353552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist.
    van Bezooijen RL; Roelen BA; Visser A; van der Wee-Pals L; de Wilt E; Karperien M; Hamersma H; Papapoulos SE; ten Dijke P; Löwik CW
    J Exp Med; 2004 Mar; 199(6):805-14. PubMed ID: 15024046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Localization of SOST/sclerostin in cementocytes in vivo and in mineralizing periodontal ligament cells in vitro.
    Jäger A; Götz W; Lossdörfer S; Rath-Deschner B
    J Periodontal Res; 2010 Apr; 45(2):246-54. PubMed ID: 19778325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2.
    Kogawa M; Wijenayaka AR; Ormsby RT; Thomas GP; Anderson PH; Bonewald LF; Findlay DM; Atkins GJ
    J Bone Miner Res; 2013 Dec; 28(12):2436-48. PubMed ID: 23737439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does osteocytic SOST suppression mediate PTH bone anabolism?
    Kramer I; Keller H; Leupin O; Kneissel M
    Trends Endocrinol Metab; 2010 Apr; 21(4):237-44. PubMed ID: 20074973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sclerostin, an osteocytes-derived bone-forming inhibitor.
    Włodarski KH; Galus R; Brodzikowska A; Włodarski PK
    Pol Orthop Traumatol; 2013 Jul; 78():151-4. PubMed ID: 23820854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteocyte control of bone remodeling: is sclerostin a key molecular coordinator of the balanced bone resorption-formation cycles?
    Sapir-Koren R; Livshits G
    Osteoporos Int; 2014 Dec; 25(12):2685-700. PubMed ID: 25030653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes.
    Kim JY; Lee SK; Jo KJ; Song DY; Lim DM; Park KY; Bonewald LF; Kim BJ
    Life Sci; 2013 Mar; 92(10):533-40. PubMed ID: 23357248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist.
    Winkler DG; Sutherland MK; Geoghegan JC; Yu C; Hayes T; Skonier JE; Shpektor D; Jonas M; Kovacevich BR; Staehling-Hampton K; Appleby M; Brunkow ME; Latham JA
    EMBO J; 2003 Dec; 22(23):6267-76. PubMed ID: 14633986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling.
    ten Dijke P; Krause C; de Gorter DJ; Löwik CW; van Bezooijen RL
    J Bone Joint Surg Am; 2008 Feb; 90 Suppl 1():31-5. PubMed ID: 18292354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human primary osteocyte differentiation in a 3D culture system.
    Boukhechba F; Balaguer T; Michiels JF; Ackermann K; Quincey D; Bouler JM; Pyerin W; Carle GF; Rochet N
    J Bone Miner Res; 2009 Nov; 24(11):1927-35. PubMed ID: 19419324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A sclerostin-based theory for strain-induced bone formation.
    van Oers RF; van Rietbergen B; Ito K; Hilbers PA; Huiskes R
    Biomech Model Mechanobiol; 2011 Oct; 10(5):663-70. PubMed ID: 21069416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anti-sclerostin antibodies].
    Okazaki R
    Clin Calcium; 2011 Jan; 21(1):94-8. PubMed ID: 21187600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation.
    van Bezooijen RL; Svensson JP; Eefting D; Visser A; van der Horst G; Karperien M; Quax PH; Vrieling H; Papapoulos SE; ten Dijke P; Löwik CW
    J Bone Miner Res; 2007 Jan; 22(1):19-28. PubMed ID: 17032150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation.
    van Bezooijen RL; ten Dijke P; Papapoulos SE; Löwik CW
    Cytokine Growth Factor Rev; 2005 Jun; 16(3):319-27. PubMed ID: 15869900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTH/PTHrP receptor expression on osteoblasts and osteocytes but not resorbing bone surfaces in growing rats.
    Fermor B; Skerry TM
    J Bone Miner Res; 1995 Dec; 10(12):1935-43. PubMed ID: 8619374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biological function of bone cells on the PTH-driven anabolic effect].
    Hasegawa T; Hongo H; Sasaki M; Yamada T; Amizuka N
    Clin Calcium; 2012 Mar; 22(3):373-9. PubMed ID: 22370304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone remodeling in the context of cellular and systemic regulation: the role of osteocytes and the nervous system.
    Niedźwiedzki T; Filipowska J
    J Mol Endocrinol; 2015 Oct; 55(2):R23-36. PubMed ID: 26307562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody.
    Padhi D; Jang G; Stouch B; Fang L; Posvar E
    J Bone Miner Res; 2011 Jan; 26(1):19-26. PubMed ID: 20593411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.